Pinned Tweet
GLP-1 drugs in #IBD are a hot talking point at the moment - and they're throwing up some interesting findings, to boot.
We've just had a VERY special expert guest confirmed for our podcast hot seat on this one! 🤩 So please do send us your questions on this topic. Thanks.
The Bottom Line IBD retweeted
The surgeon drives, the geriatrician is the airbag.
Screen the #Frail & the #Elderly before #Colorectal MDT - a few minutes of bedside tests - and call the geriatrician if positive. Outcomes will follow!
75'' recap👇 Full lecture by @3isac link below - free until 3 Nov #THRIVE2027
The Bottom Line IBD retweeted
Excited to share our latest publication in @BMJDigitalHealth! 🚀
In just 6 months, @ChatIBDapp reached 913 users across 69 countries, generating 7,222 messages in 28 languages 🌍
A first step towards guideline-grounded AI in #IBD care. Formal validation is next!
Congrats to @drshaunchuah the brilliant mind behind this and to Nik Plevris
doi.org/10.1136/bmjcdh-2026-…
The Bottom Line IBD retweeted
Is proximal small bowel Crohn worse than distal bcs the Tx is less effective there?
Well, No...
In our @sheba_medical #capsule study now published in @AGA_CGH , biologics induced similar mucosal healing in proximal vs distal SB.
@OffirU @HelmsleyTrust
cghjournal.org/article/S1542…
The Bottom Line IBD retweeted
🎯 STRIDE-III is here!
The new treat-to-target framework for #IBD, presented at #UEGWeek2026 and published in @LancetGastroHep.
🔑 The big shift: not every target asks for the same thing.
🔴 Actionable → miss it, change treatment
🟡 Adjunctive (NEW) → histology in UC, transmural healing in CD, urgency: optimise & monitor
🟢 Patient-centred → fatigue, disability, QoL: shared decisions
📊 1,018 studies · modified Delphi · ≥75% agreement
👇 The whole framework in one image
🔗 doi.org/10.1016/S2468-1253(2…
@myueg
#MedTwitter #GITwitter #MedEd #IBD #CrohnsDisease #UlcerativeColitis
The Bottom Line IBD retweeted
🎯 Should we treat UC all the way to histology? VERDICT says... maybe not!
📍 672 adults with moderate–severe UC on vedolizumab, randomised to 3 treat-to-target strategies (#UEGWeek2026 late-breaker)
🔬 Reaching disease clearance (symptoms + endoscopy + histology) → 67% lower risk of UC complications vs a symptom-only target
📉 HR 0.33 (95% CI 0.17–0.67), p=0.0014
🤔 Endoscopic target vs full clearance: no difference (HR 1.10)
⚠️ Analysis only includes patients who reached their target (59.5%)
👇 The whole trial in one image
🔗 takeda.com/newsroom/newsrele…
@my_ueg
#MedTwitter #GITwitter #MedEd #IBD #UlcerativeColitis #TreatToTarget
Pleased to say that Nigel & I now have a confirmed recording date for our fatigue in IBD podcast episode. Sorry this one took so long!
Then we're off on a virtual visit to the US to record the next trio: GLP-1s in IBD (massive interest right now); pain management; and IBD Qorus.
The Bottom Line IBD retweeted
A welcome step forward in Crohn’s disease care!
I am excited about the FDA approval of subcutaneous induction with risankizumab (SKYRIZI) for Crohn’s disease.
Having cared for patients with IBD for many years, I have seen how the burden of treatment extends well beyond the disease itself. Traveling to infusion centers, taking time away from work, arranging transportation, and balancing treatment with everyday life can be challenging.
The ability to initiate treatment at home offers patients something valuable: greater flexibility, convenience, and potentially more control over their treatment journey.
The encouraging clinical and endoscopic outcomes from the AFFIRM trial make this development even more meaningful.
Of course, convenience must be accompanied by efficacy, safety, affordability, and access.
I see this as another positive step toward making effective IBD care fit better into patients’ lives, rather than asking patients to continually rearrange their lives around treatment.
Innovation in IBD should not only improve outcomes. It should also improve the patient experience.
#IBD #CrohnsDisease #SKYRIZI #PatientCenteredCare #IBDLibrary
linkedin.com/posts/ibd-libra…
The Bottom Line IBD retweeted
What changes from STRIDE-II to STRIDE-III? Presented at #UEGWeek2026
• Targets split into actionable, adjunctive & patient-centred
• FC: <200 µg/g; <100 for deeper control
• Urgency and fatigue now included
• Adapted tools for resource-limited settings
#IBD #weareUEG
🤖 Made with AI
The Bottom Line IBD retweeted
For latest episode of our “Wrestling The Octopus IBD” podcast we were joined by Sue Blackwell @littlemissileo a UC patient who, through involvement with research, recently gained a PhD on parastomal hernias. We talked about #stomas, J pouches & #GLP1, amongst others things
The Bottom Line IBD retweeted
In 2000, a flood in Walkerton, Canada contaminated the water and sickened an entire town. It was a revealing example of the gut-brain axis in action.
psychologytoday.com/us/blog/…
The Bottom Line IBD retweeted
🧠 Stay informed in digestive health with the UEG Newsletter.
Get:
✔ Expert insights & research
✔ Educational content
✔ Career opportunities
✔ UEG news & events
📩 Subscribe today: ueg.eu/p/222
ALT a black tablet with a green alligator on it
The Bottom Line IBD retweeted
Could where body fat is stored help identify fracture risk in people with IBD? Read the paper by Suntharalingam et al. on “Regional fat distribution as a novel predictor of fracture risk in IBD…” via bit.ly/4AnT6Kg #BMJOG #BMJOGPapers @ChristianSelin3
The Bottom Line IBD retweeted
STRIDE III guidelines presented at UEGWeek @my_ueg Manuscript is published as well thelancet.com/journals/langa…
The Bottom Line IBD retweeted
Could GLP-1-based therapies affect how quickly a capsule travels through the ileum? Read the paper by Abu Baker et al. on “Association between GLP-1-based therapy and small-bowel transit time during capsule endo…” via bit.ly/4xvJ2MD #BMJOG #BMJOGPapers @ChristianSelin3
